In the single-centre Abatacept Sjögren Active Patients phase III (ASAP-III) study, no difference was seen in disease activity (as measured by ESSDAI) in patients with primary Sjögren syndrome (pSS) treated with abatacept (n = 40) compared with those who received placebo (n = 39) after 24 weeks. Patient-reported symptoms (as measured by ESSPRI) also did not differ between the groups, although IgG and rheumatoid factor concentrations were decreased in the abatacept group at 24 weeks. Further studies are needed to evaluate the effects of abatacept on specific systemic manifestations of pSS.
References
Original article
van Nimwegen, J. F. et al. Abatacept treatment for patients with early active primary Sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(19)30160-2 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Abatacept no better than placebo for pSS. Nat Rev Rheumatol 16, 186 (2020). https://doi.org/10.1038/s41584-020-0390-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0390-8
